Skip to main content
SpringerLink
Log in

Paclitaxel in Peripheral Vascular Disease: Guilty Until Proven Innocent

  • Commentary
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wikipedia. Presumption of innocence (2019). https://en.wikipedia.org/wiki/Presumption_of_innocence

  2. Inman T. Foundation for a new theory and practice of medicine. London: John Churchill; 1860.

    Google Scholar 

  3. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245.

    Article  Google Scholar 

  4. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Response to letter by Bonassi on Article, "Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-analysis of Randomized Controlled Trials". J Am Heart Assoc. 2019;8(10):e012172.

    Article  Google Scholar 

  5. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the zilver PTX randomized trial. Circulation. 2019;139(8):e42.

    Google Scholar 

  6. Schneider PA, Laird JR, Doros G, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol. 2019;73(20):2550–63

    Article  Google Scholar 

  7. Agency FD. June 19–20, 2019: Circulatory system devices panel of the medical devices advisory committee meeting announcement (2019). https://www.fda.gov/advisory-committees/advisory-committee-calendar/june-19-20-2019-circulatory-system-devices-panel-medical-devices-advisory-committee-meeting#event-materials,

  8. Schneider PA, Laird JR, Doros G, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol. 2019;73(20):2550–633.

    Article  Google Scholar 

  9. Ouriel K, Adelman MA, Rosenfield K, et al. Safety of paclitaxel-coated balloon angioplasty for femoropopliteal peripheral artery disease. JACC Cardiovasc Interv. 2019. https://doi.org/10.1016/j.jcin.2019.08.025.

    Article  PubMed  Google Scholar 

  10. Gray WA, Jaff MR, Parikh SA, et al. Mortality assessment of paclitaxel-coated balloons: patient-level meta-analysis of the ILLUMENATE clinical program at 3 years. Circulation. 2019;140(14):1145–55.

    Article  CAS  Google Scholar 

  11. Klumb C, Lehmann T, Aschenbach R, Eckardt N, Teichgraber U. Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2019;16:42–50.

    Article  Google Scholar 

  12. Secemsky EA, Kundi H, Weinberg I, et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019;4(4):332–40.

    Article  Google Scholar 

  13. Freisinger E, Koeppe J, Gerss J, et al. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. Eur Heart J. 2019. https://doi.org/10.1093/eurheartj/ehz698.

    Article  PubMed  Google Scholar 

  14. Long CA, Zepel L, Greiner MA, Hammill BG, Patel MR, Jones WS. Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease. Am Heart J. 2019;217:42–51.

    Article  Google Scholar 

  15. Donas KP, Sohr A, Pitoulias GA, Alfonso F, Torsello G. Long-term mortality of matched patients with intermittent claudication treated by high-dose paclitaxel-coated balloon versus plain balloon angioplasty: a real-world study. Cardiovasc Intervent Radiol. 2019. https://doi.org/10.1007/s00270-019-02329-z.

  16. Holden A, Varcoe RL, Jaff MR, Schneider PA, Tepe G, Zeller T. Paclitaxel and mortality: the dose argument is critical. J Endovasc Ther. 2019;26(4):467–70.

    Article  Google Scholar 

  17. Dake MD, Ansel GM, Bosiers M, et al. (2019) Paclitaxel-coated zilver PTX drug-eluting stent treatment does not result in increased long-term all-cause mortality compared to uncoated devices. Cardiovasc Intervent Radiol. 2019. https://doi.org/10.1007/s00270-019-02324-4.

  18. Tzafriri AR, Parikh SA, Edelman ER. Taking paclitaxel coated balloons to a higher level: predicting coating dissolution kinetics, tissue retention and dosing dynamics. J Control Release. 2019;310:94–102.

    Article  CAS  Google Scholar 

  19. Tzafriri AR, Vukmirovic N, Kolachalama VB, Astafieva I, Edelman ER. Lesion complexity determines arterial drug distribution after local drug delivery. J Control Release. 2010;142(3):332–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Interventional Radiology, Patras University Hospital, 26504, Rion, Greece

    Konstantinos Katsanos, Panagiotis Kitrou & Dimitrios Karnabatidis

  2. Attikon University Hospital, Athens, Greece

    Stavros Spiliopoulos

  3. Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

    Miltiadis Krokidis

Authors
  1. Konstantinos Katsanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Panagiotis Kitrou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stavros Spiliopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miltiadis Krokidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dimitrios Karnabatidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konstantinos Katsanos.

Ethics declarations

Conflict of interest

For the purposes of this project, no author received any payment or other supports from a commercial company. Dr Katsanos reports personal fees from Boston Scientific and Philips outside the submitted work. Dr Kitrou reports personal fees from BD outside the submitted work. Dr Karnabatidis reports personal fees and grants from BD outside the submitted work. The remaining authors have no financial disclosures to report.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Katsanos, K., Kitrou, P., Spiliopoulos, S. et al. Paclitaxel in Peripheral Vascular Disease: Guilty Until Proven Innocent. Cardiovasc Intervent Radiol 43, 20–22 (2020). https://doi.org/10.1007/s00270-019-02390-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-019-02390-8

Search

Navigation